VR Logo

BridgeBio Pharma Inc. (BBIO) download report


Healthcare | Biotechnology & Pharma Research

BridgeBio Pharma Inc. (BBIO) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases.

IPO Date: 27-Jun-2019

Co-Founder, Pres, CEO & Director: Dr. Neil Kumar Ph.D.

Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director: Dr. Charles J. Homcy M.D.

Listing: NASDAQ: BBIO

Country: United States

Headquarters: Palo Alto, CA

Website: https://www.bridgebio.com

Key Facts

Market cap: $1,248.01 Mln

Revenue (TTM): $70.95 Mln

Earnings (TTM): $-595.86 Mln

Cash: $671.23 Mln

Total Debt: $1,727.91 Mln

Insider's Holding: 7.33%

Liquidity: Low

52 Week range: $4.98 - 65.33

Shares outstanding: 147,694,000

5 Years Aggregate:

  • CFO: $-1,328.37 Mln
  • EBITDA: $-1,397.52 Mln
  • Net Profit: $-1,433.16 Mln

Stock Performance

Time Period BridgeBio Pharma (BBIO) S&P BSE Sensex S&P Small-Cap 600
YTD-44.60-9.49-17.79
1 month25.89-2.87-2.72
3 months-14.13-8.59-12.17
1 Year-84.430.81-15.82
3 Years--10.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year BridgeBio Pharma (BBIO) S&P Small-Cap 600 S&P BSE Sensex
2021-76.5425.2721.99
2020102.889.5715.75